Fructose-induced Intestinal de Novo Lipogenesis

Obesity Clinical Trial

— FIDNL  

Official title:

Measure of Intestinal Lipogenesis in Healthy Volunteers and Obese Subjects Before and After Gastroplasty: Modulation by Glucose and Fructose

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01792089
• Other study ID #: 193/11
• Status: Completed
• Start date: February 2013
• Est. completion date: December 2016

Study information

• Verified date: March 2019
• Source: University of Lausanne
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

8 healthy volunteers, 8 pre-bypass obese subjects, 8 subjects between 12-18 months post-bypass, and 8 subjects matched to the post-bypass patients will be studied in two sub-studies Sub-study 1) after ingestion of two or three different of the following test-meals: A)cream and whey protein B)cream, whey protein and fructose + 13C6 fructose C)test meal with cream, whey protein, fructose and glucose + 13C6 fructose Their intestinal de novo lipogenesis will be estimated by measuring 13C-palmitate on triglyceride-rich lipoprotein particles associated with apoB48 in blood Sub-study 2) after ingestion of two or three different of the following test-meals: A)cream labelled with 13C6 palmitic acid and whey protein B))cream labelled with 13C6 palmitic acid, whey protein, fructose and glucose

Their intestinal de novo lipogenesis will be estimated by measuring 13C-palmitate on triglyceride-rich lipoprotein particles associated with apoB48 in blood in sub-study 1

Their exogenous lipid absorption kinetics will be assessed by measuring 13C palmitate on triglyceride-rich lipoprotein particles associated with apoB48 in sub-study 2

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: December 2016
• Est. primary completion date: December 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 25 Years to 50 Years

Eligibility

Inclusion Criteria:

• age 18-50 years

• sex male or female

• less than 2 kg body weight change over the past 3 months subjects

Exclusion Criteria:

• antidiabetic and hypolipemic drugs

• alcohol consumption >20g/day

• severe eating disorders

• severe psychological problems

• vegetarian diet or other specific diet

• consumption of illicit substances

• pregnancy

• weight gain or weight loss > 1 kg in the last 3 months

Related Conditions & MeSH terms

• Obesity

Intervention

Other:
• fat+protein meal
cream+ whey protein
• Fat + protein + 13C fructose meal
cream+ whey protein +13C fructose
• Fat+protein+13C fructose+glucose meal
Cream + whey protein + glucose:13C fructose mixture
• 13C Fat + whey protein
cream labelled with 13C palmitate + whey protein
• 13C Fat + whey protein + glucose+ glucose meal
cream labelled with 13C palmitate + whey protein + glucose:fructose mixture

Locations

Country	Name	City	State
Switzerland	Centre Hospitalier Universitaire Vaudois	Lausanne	VD

Sponsors (1)

Lead Sponsor	Collaborator
University of Lausanne

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Intestinal de novo lipogenesis (sub-study 1)	Measurement of total TG and 13C palmitate in chylomicrons: The sf >20 fraction of post-prandial blood samples will be prepared, and non-chylomicrons, apoB100-containing lipoprotein will be removes by immuno-affinity chromatography using a specific anti-apoB100 antibody	0-8-hour post-prandial
Primary	Postprandial exogenous, labelled palmitate concentration (sub-study 2)	Measurement of total TG and 13C palmitate in chylomicrons of sf >20 fraction of post-prandial blood samples will be prepared,	0-8-hour post-prandial
Secondary	post-prandial triglyceride profile (sub-studies 1 and 2	Triglyceride will be measured in the chylomicron, VLDL, LDL and HDL fractions of post-prandial blood samples	0-8 hour post-prandial